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Abstract
Background: The commercial test, SeptiFast, is designed to detect DNA from bacterial and fungal pathogens in
whole blood. The method has been found to be specific with a high rule-in value for the early detection of septic
patients. The software automatically provides information about the identified pathogen, without quantification of
the pathogen. However, it is possible to manually derive Crossing point (Cp) values, i.e. the PCR cycle at which DNA
is significantly amplified. The aim of this study was to find out whether Cp values correlate to disease severity.
Methods: We used a study cohort of patients with positive results from SeptiFast tests for bacteria from a recent
study which included patients with suspected sepsis in the Emergency department. Cp values were compared with
disease severity, classified as severe sepsis/septic shock or non-severe sepsis, according to the criteria of the
American College of Chest Physicians/Society of Critical Care Medicine.
Results: Ninety-four patients were included. The prevalence of severe sepsis/septic shock in the study was 29%.
SeptiFast positive tests from patients with severe sepsis/septic shock had significantly lower Cp values compared
with those from patients with non-severe sepsis, median 16.9 (range: 7.3 - 24.3) versus 20.9 (range: 8.5 - 25.0),
p < 0.001. Positive predictive values from the SeptiFast test for identifying severe sepsis/septic shock were 34% at
Cp cut-off <25.0, 35% at Cp cut-off <22.5, 50% at Cp cut-off <20.0, and 73% at Cp cut-off <17.5. Patients with a
positive Septifast test with a Cp value <17.5 had significantly more severe sepsis/septic shock (73% versus 15%,
p < 0.001), were more often admitted to the Intensive Care Unit (23% versus 4%, p = 0.016), had positive blood
culture (BC) more frequently (100% versus 32%, p < 0.001) and had longer hospital stays (median 19.5 [range: 4 - 78]
days versus 5 [range: 0 - 75] days, p < 0.001) compared with those with a Cp value >17.5.
Conclusions: Our results suggest that introducing quantitative data to the SeptiFast test could be of value in
assessing sepsis severity. Moreover, such data might also be useful in predicting a positive BC result.
Background
Bloodstream infections are associated with high morbidity
and mortality rates worldwide [1,2]. Prompt administra-
tion of adequate antibiotics is crucial for successfully
treating severe sepsis and septic shock [3,4]. Blood cul-
ture (BC) is the current ‘gold standard’ for diagnosing
bloodstream infections, but the method has several lim-
itations. Firstly, the method has a low sensitivity both to
slow-growing and fastidious organisms [5] and when
antibiotics have been given prior to culture [6,7]. Previ-
ous studies have shown that a positive BC is only found
in about 30% of patients with severe sepsis and septic
shock [8]. Secondly, it takes between 24 to 72 hours
before the pathogen is identified. By implementing new
techniques, such as matrix-assisted laser desorption
ionization-time of flight (MALDI-TOF), the time to
pathogen identification can be significantly shortened,
and it has been shown that this reduction has a significant
effect on the time to adequate antibiotic treatment [9,10].
For better, more appropriate initial antibiotic treatment,
techniques that can confirm the infectious aetiology as
soon as possible are needed. Using polymerase chain re-
action (PCR) analysis to detect bacterial DNA in blood
* Correspondence: ingrid.ziegler@orebroll.se
1Department of Infectious Diseases, Örebro University Hospital, S-701 85
Örebro, Sweden
2School of Health and Medical Sciences, Örebro University, Örebro, Sweden
Full list of author information is available at the end of the article
© 2014 Ziegler et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Ziegler et al. BMC Infectious Diseases 2014, 14:155
http://www.biomedcentral.com/1471-2334/14/155
samples provides a result within hours, and is virtually
unaffected by the prior use of antibiotics [5]. Addition-
ally, PCR enables the quantification of bacterial DNA.
For broad, routine use of PCR techniques in sepsis
diagnostics, there is a need for validated commercial as-
says. There are already a few commercial tests available
for the molecular identification of pathogens directly on
blood samples [11-13]. Among such tests, the Light Cycler
SeptiFast Test (Roche Diagnostics) is, to date, the most
used and investigated in clinical studies [14], and it has
been approved for clinical use in Europe. The method has
been evaluated in a systematic review [15], and was found
to be specific, with a high rule-in value for the early
detection of septic patients. The SeptiFast test is used
for pathogen identification, but the result does not
include any quantitative information.
The diagnosis of sepsis is sometimes difficult, and for
the clinician it is a major challenge to, as early as possible,
identify patients at risk from septic shock and death. In
addition to the clinical evaluation, laboratory tests are cur-
rently the main diagnostic tools used in the initial assess-
ment. Thus, a rapid molecular test that can contribute to
predicting the risk of developing severe sepsis or septic
shock would be of significant clinical value. Previous
studies have shown that a high bacterial DNA load in
the blood is related to a more severe disease, an increased
risk of developing septic shock, and consequently a poor
prognosis [16-20]. Given this, our aim was to study
whether quantitative data from the commercial SeptiFast
test could inform disease severity.
For this purpose, we used a study cohort of patients with
positive Septifast test results from a recent prospective
study [21]. The manufacturer provided access to Crossing
point (Cp) values for all positive PCR results. A Cp value
represents the PCR cycle at which DNA is significantly
amplified, and it is generally accepted as an indirect and
inverse marker of the DNA load.
In the present study, our aim was to investigate whether
the level of the Cp values could differentiate cases with




The department of Infectious Diseases, Örebro University
Hospital, Sweden, serves a population of 275,000 inhab-
itants in the county of Örebro, and is organised into an
outpatient clinic and a ward for 30 adult patients.
In the prospective study [21], all patients who were
subjected to BC in the department from October 2007
to September 2008, and who gave their informed consent,
were enrolled. If the patient was unable to provide consent
due to illness, a next-of-kin was permitted to give the
consent, or it could be given the next day. This study
approach was approved by the regional ethical review
board in Uppsala, Sweden. Blood samples for PCR analysis
were taken at the same time as BC from all participating
patients. The results of the PCR assays were unknown to
the clinicians until the closure of the study. In total 1,093
patients were included in the study, and 113 positive
SeptiFast PCR were found in 107 patients. In 50 of them,
the same pathogen was also found in the BC. These 107
patients form the study population in the present study.
As our aim was to study bacteria, we excluded four
cases which tested positive for fungi. Ten cases which
were positive for coagulase-negative staphylococci (CoNS)
were excluded, as they had no microbiological or clinical
support for infection with CoNS, and were considered
to represent skin contamination. In the end, 99 positive
PCR tests from 94 patients were included in the study.
Laboratory analyses
BC was performed with the Bactec system (Becton Dickinson
and Company, Sparks, MD, USA), with a Bactec 9240
incubator, and culture duration time of 7 days. For each
BC, a volume of 8–10 ml of venous blood was inoculated
in one Bactec PlusAerobic/F bottle and the same volume
in one Bactec Plus Anaerobic/F bottle.
Whole blood was collected in sterile EDTA tubes
through the same venepuncture from which the blood
samples for BC were taken. The whole blood was then
stored for a maximum of 4 hrs at room temperature, or
up to 3 days at +4°C, or 3 months at −70°C prior to DNA
preparation. DNA was extracted manually from 1.5 mL of
the EDTA blood, using the SeptiFast Prep KitMGRADE
(Roche Diagnostics GmnH). At the extraction step, an
internal control was added to each sample. A negative
control supplied by the manufacturer was included in
each extraction series, and reagent controls were used
as a positive control of the PCR reactions. Quantitative
PCR was performed using The SeptiFast method, which
is described in details elsewhere [21]. In the SeptiFast
test, the internal transcribed spacer (ITS) region is used
as the target to specifically distinguish 25 different bacter-
ial and fungal pathogens (Table 1). For the Gram-positive
assay, the analysis is based on melting peaks and Cp
values. To reduce false-positive results from assumed con-
taminants, the software includes Cp cut-off values, e.g., for
Streptococcus species, this cut-off value is at 20 cycles, and
for other Gram-positives at 25 cycles. We have no access
to data from samples with Cp values above this cut-off, as
the test results were then reported as negative. The assay
for Gram-negative bacteria is solely based on melting
peaks, and there are no Cp cut-off values. However, for
test results that are positive for Gram-negatives with a Cp
value above 25 cycles, the software reports only Cp >25,
and provides no continuous variable. In this study, 12
cases with PCR positive for Gram-negatives with Cp
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values above 25 were included. In the statistical analyses
we have given them a Cp value of 25.0.
Crossing point (Cp)
During PCR, the amount of PCR product formed is mea-
sured at each cycle and reported in fluorescence units. In
the SeptiFast test, this starts after cycle six, as the first
cycles only focus on annealing at different temperatures.
The more target DNA present in a sample, the quicker a
significant PCR product is generated. A sample is positive
if the amount of fluorescence produced rises above a
defined threshold level. At that point, a crossing point
(Cp) value is created, showing how many PCR cycles are
required to reach the threshold level. Thus, the more
target DNA present in a sample, the lower the Cp value
will be. The Cp value is the term used in LightCycler, and
is the same as the threshold cycle (Ct) value in other PCR
assays.
Clinical data and definitions
A retrospective chart review was performed by a special-
ist in Infectious Diseases (I.Z.) to evaluate the severity of
illness, without prior knowledge of the SeptiFast data.
Data collected included demographic details, underlying
diseases, source of infection, antibiotic treatment, length
of hospital stay, intensive care unit (ICU) admission and
mortality. Laboratory parameters and clinical observations
(heart rate, blood pressure, temperature, respiratory
rate, pulse oximetry) from the time of admission were
recorded. The patient’s clinical condition on admission
was classified as systemic inflammatory response syn-
drome (SIRS), sepsis, severe sepsis or septic shock by
using the criteria published by the American College of
Chest Physicians/Society of Critical Care Medicine (ACCP/
SCCM) [22], see Table 2.
Statistics Medians and ranges were used for descriptive
statistics of continuous variables, and percentages for cat-
egorical variables. Comparison of groups was performed
using the Mann–Whitney-U test for continuous variables
and the Chi-square or Fischer’s exact test for categorical
variables. A p-value of < 0.05 was regarded as signifi-
cant. Positive predictive values were calculated from
cross-tabulations. The IBM SPSS Statistics, version 21,
New York, USA, was used for calculations.
Results
Study population
In Table 3, demographic data and clinical characteristics
are shown for the 94 patients with positive SeptiFast
PCR. The main foci of infection were the urinary tract
(n = 27, 29%), the gastrointestinal/bilary tract (n = 11,
12%), the skin (n = 11, 12%), orthopaedic (n = 10, 11%)
and the chest (n = 9, 10%). Six (6%) patients had an
unknown focus of sepsis and 15 (16%) had no evidence
of bacterial infection.
The pathogens most frequently detected with the
SeptiFast test in the study were Escherichia coli (n = 33),
Staphylococcus aureus (n = 24), Streptococcus species
Table 1 Bacteria and fungi detectable by the SeptiFast
assay according to the manufacturer
Gram-negative Gram-positive Fungi











Enterobacter cloacae Streptococcus pyogenes Candida glabrata
Enterobacter aerogenes Streptococcus agalactiae Aspergillus
fumigatus
Proteus mirabilis Streptococcus mitis
Pseudomonas aeruginosa Enterococcus faecium
Acinetobacter baumannii Enterococcus faecalis
Stenotrophomonas
maltophilia
Table 2 SIRS and Sepsis Definition (ACCP/SCCM criteria)
SIRS systemic inflammatory
response syndrome
Sepsis Severe sepsis Septic shock




with 2 or more SIRS
criteria.
Sepsis-induced tissue hypoperfusion or organ
dysfunction, including hypotension, lactic acidosis,
oliguria, hypoxemia, coagulation disorders and
acute alteration in mental status.
Sepsis with hypotension, despite
adequate fluid resuscitation,
along with the presence of perfusion
abnormalities.
• Temperature > 38°C
or <36°C
• Heart rate > 90/min
• Respiratory rate > 20/min
or PaCO 2 < 32 mmHg
(4.3 kPa)
• WBC > 12 × 109 /L, < 4 ×
109/L, or > 10% immature forms
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(n = 13) and Klebsiella pnemoniae/oxytoca (n = 13).
Four patients were PCR positive for more than one
pathogen (Table 4). Noteworthy is that only 2 cases
with Streptococcus pneumoniae were detected. This is
due to the SeptiFast test’s very low sensitivity to S.
pneumoniae in the prospective study, only 12% (PCR
positive/BC positive =2/16) [21].
Of all 94 patients with positive SeptiFast PCR, 27
patients had severe sepsis or septic shock upon arrival,
according to the criteria of ACCP/SCCM. Thirty out of
99 positive PCR results were found in patients with
severe sepsis/septic shock.
Cp values in relation to severity of disease
An overview of all bacteria found by SeptiFast PCR in
the study, divided into samples from patients with severe
sepsis/septic shock or non-severe sepsis, is shown in
Table 5. The Cp values were significantly lower in the
group with severe sepsis/septic shock compared with the
group with non-severe sepsis in the study population.
This was also shown in the sub-groups with positive
PCR test for S. aureus, Streptococcus species and E. coli
(Table 5).
Tables 6 and 7 demonstrate positive predictive values
(PPV) with different cut-off limits for the detection of
severe sepsis/septic shock for the most frequently found
pathogens and for all Gram-positive and Gram-negative
bacteria. The positive predictive values of the SeptiFast
test for detection of severe sepsis/septic shock in the entire
study population are illustrated in Figure 1, and were 34%
at SeptiFast Cp cut-off <25, 35% at Cp cut-off <22.5, 50%
at Cp cut-off <20, and 73% at Cp cut-off <17.5.
In Table 3, clinical characteristics for patients with
Cp <17.5 and >17.5 are presented separately. Patients
Table 3 Demographic and clinical characteristics of the patients with a positive SeptiFast test
All patients (n=94) Patients with Cp >17.5 (n=72) Patients with Cp <17.5 (n=22) P-value for comparison
Female 35 (37%) 26 (36%) 9 (41%) 0.80
Age, years 74 (14-96) 69 (25-96) 74 (14-93) 0.36
Co-morbidities
Heart disease 22 (23%) 14 (20%) 8 (36%) 0.12
Neurological disease 13 (14%) 8 (11%) 5 (23%) 0.18
Chronic renal failure 12 (13%) 10 (14%) 2 (9%) 0.54
Neoplasms 17 (18%) 14 (20%) 3 (14%) 0.50
Clinical data
Antibiotics before analyses 20 (21%) 15 (21%) 5 (23%) 0.85
Blood culture positivity 45 (48%) 23 (32%) 22 (100%) <0.001
C-reactive protein 108 (1-446) 93 (1-372) 212 (12-446) 0.002
Body temperature, C° 38.7 (37.0-41.4) 38.7 (37.1-41.0) 38.8 (37.0-41.4) 0.89
> 2 SIRS criteria 82 (87%) 61 (85%) 21 (96%) 0.19
Severe sepsis/septic shock 27 (29%) 11(15%) 16 (73%) <0.001
Septic shock 3 (3%) 0 3 (14%) 0.01
Hospitalisation length, days 7 (0-78) 5 (0-75) 19.5 (4-78) <0.001
Intensive care unit admission 8 (9%) 3 (4%) 5 (23%) 0.016
1 month mortality rate 8 (9%) 4 (6%) 4 (18%) 0.084
Data are presented as numbers (percentages) for categorical variables and as median values (ranges) for continuous variables.
Table 4 Patients with a positive SeptiFast test for more than one pathogen
Sex, age Focus of
infection




Cholangitis Escherichia coli (Cp:13.69), Klebsiella pneumoniae/oxytoca
(Cp:11.20)







Escherichia coli (Cp:13.95), Klebsiella pneumoniae/oxytoca
(Cp:17.01) Streptococcus species (Cp:16.67)












Enterobacter cloacae (Cp:8.47), Enterococcus faecalis (Cp:8.76) Enterobacter cloacae, Enterococcus faecalis No
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with Cp <17.5 do not differ in demographics compared
to those with Cp > 17.5, but have significantly more se-
vere sepsis, develop septic shock more often, require
ICU treatment more often, and have longer hospital stays.
We have not calculated negative predictive values (NPV),
sensitivities and specificities, as we have no data on the
number of patients with severe sepsis/septic shock and
negative SeptiFast tests.
Eight patients with severe sepsis/septic shock attended
the ICU with a median Cp value of 16.3 (range: 7.3 -
25.0). Among them, 3 patients were given advanced in-
tensive care, including inotropic drugs and mechanical
ventilation; all three were BC positive. One of them, an
elderly man with spondylitis and a SeptiFast test that
was positive for S. aureus, with a Cp value of 14.6, died.
The other two patients survived; a young girl with an
epidural abscess and a SeptiFast test that was positive
for Streptococcus species, Cp 16.6, and an elderly lady with
a lung abscess and a SeptiFast test which was positive for
S. pneumoniae, Cp 7.3.
Among the 24 patients where S. aureus was found in
PCR, four patients had endocarditis, all of them were
BC positive and two of them had severe sepsis/septic
shock. The median Cp value for patients with endocarditis
was 13.6 (range: 10.4 - 18.6), compared with 20.2 (range:
12.1 - 22.2) for the other cases with positive S. aureus PCR
(p = 0.007).
BC results in relation to severity of disease and Cp values
The frequency of severe sepsis/septic shock was higher
among BC positive cases, 47% (23/49) compared with BC
negative ones, 14% (7/50) throughout the entire study
cohort (p < 0.001).
Median Cp values were lower in samples from patients
with positive BC compared with those from BC negative
patients: 17.2 (range: 7.3 - 25) versus 21.5 (range: 18.6 -
25.0) throughout the entire study cohort (p < 0.001); 16.4
(range: 10.4 - 21.7) vs 20.9 (range: 20.0 - 22.2) in samples
positive for S. aureus (p < 0.001); 16.9 (range: 14.7 - 19.9)
vs 19.6 (range: 18.6 - 19.8) in samples positive for
Table 5 Number of positive samples and median Crossing point (Cp) values of all bacteria detected by Septifast PCR,
grouped into severe sepsis/septic shock and non-severe sepsis cases
Species identified by Septifast Severe sepsis/septic shock Non severe sepsis P-value for comparison
between groups
No. of cases Cp median (range) No. of cases Cp median (range)
Gram positive bacteria 17 16.7 (7.3-21.7) 25 19.9 (8.8-22.2) 0.007
Staphylococcus aureus 8 16.8 (10.4-21.7) 16 20.3 (13.0-22.2) 0.045
Streptococcus speciesa 5 16.6 (14.7-16.8) 8 18.5 (17.0-19.9) 0.002
Enterococcus faecalis 2 18.1 (17.1-19.2) 1 8.8 NRb
Streptococcus pneumoniae 2 13.5 (7.3-19.8) 0 NR
Gram negative bacteria 13 17.1 (11.2-24.3) 44 21.9 (8.5-25.0) 0.004
Escherichia coli 8 16.4 (13.7-22.6) 25 21.0 (17.8-25.0) 0.006
Klebsiella pneumoniae/oxytoca 2 14.1 (11.2-17.0) 11 22.8 (20.9-25.0) NR
Enterobacter cloacae/aerogenes 2 23.6 (23.0-24.3) 3 20.5 (8.5-25.0) NR
Pseudomonas aeruginosa 1 21.6 4 23.2 (19.2-25.0) NR
Serratia marcescens 0 1 23.3 NR
Total 30 16.9 (7.3-24.3) 69 20.9 (8.5-25.0) <0.001
Comparison of median Cp values between groups.
aStreptococcus pyogenes, S. agalactiae and S. mitis bNot relevant, due to small numbers.
Table 6 Positive predictive values of Crossing point (Cp) values with different cut-off limits for detection of severe
sepsis/septic shock, for blood samples with a positive SeptiFast test for Gram-positive bacteria
Cut-off Cp value Staphylococcus aureus (n = 24) Streptococcus species (n = 13) Gram-positive bacteria,
other* (n = 5)
Gram-positive bacteria
total (n = 42)
<15.0 60% (3/5) 100% (1/1) 50% (1/2) 62% (5/8)
<17.5 62% (5/8) 71% (5/7) 67% (2/3) 67% (12/18)
<20.0 55% (6/11) 38% (5/13) 80% (4/5) 52% (15/29)
<22.5 33% (8/24) 41% (17/42)
The Septifast method has a Cp cut-off at 20 cycles for test positivity for Streptococcus species, and at 25 cycles for other Gram-positive bacteria.
Data is presented as percentages (No. of SeptiFast positive samples from patients with severe sepsis /No. of SeptiFast positive samples in total, according to cut-off).
*Including: Enterococcus faecalis (n = 3) and Streptococcus pneumonia (n = 2).
Ziegler et al. BMC Infectious Diseases 2014, 14:155 Page 5 of 9
http://www.biomedcentral.com/1471-2334/14/155
Streptococcus species (p = 0.049); and 19.6 (range: 13.7 -
25) vs 21.9 (range: 19.8 - 25.0) in samples positive for
E. coli (p = 0.008).
Discussion
To our knowledge, this is the first study which evalu-
ates quantitative data from a commercial PCR assay for
bacterial species in blood samples.
The results of the study indicate that SeptiFast Cp values
do correlate to disease severity in community onset blood-
stream infections. When the SeptiFast test is used for
pathogen identification and PCR positivity is reported, Cp
values can probably be useful in identifying patients with
severe sepsis/septic shock at an early stage of the disease.
A low Cp value, with a cut-off level at 17.5 cycles as
proposed in this study, might be used effectively as a
predictive indicator in the clinical assessment. In addition
to providing rapid information about the aetiology, a posi-
tive Septifast test with a Cp value <17.5 could be an
early signal of the risk for a more severe disease and
indicate that the BC will probably also be positive
later on.
Concordance between BC and SeptiFast PCR has been
shown to be moderate [21,23-27], with a high frequency
of PCR positive results not being confirmed by a positive
BC, and vice versa. A positive PCR but a negative BC
can occur due to fastidious microbes, sub-optimal culture
conditions or antibiotic treatment before sampling. False-
positive PCR results can occur due to contamination from
sampling tubes or reagents. To minimise such risk, the
EDTA tubes used in the study were endotoxin and DNA-
free, and high-quality PCR reagents, free of bacterial or
Table 7 Positive predictive values of Crossing point (Cp) values with different cut-off limits for detection of severe
sepsis/septic shock, for blood samples with a positive SeptiFast test for Gram-negative bacteria
Cut-off Cp value Escherichia coli (n = 33) Klebsiella pneumoniae/
oxytoca (n = 13)
Gram-negative bacteria,
other* (n = 11)
Gram-negative bacteria
total (n = 57)
<15.0 100% (3/3) 100% (1/1) 0% (0/1) 80% (4/5)
<17.5 100% (5/5) 100% (2/2) 0% (0/1) 88% (7/8)
<20.0 37% (5/11) 100% (2/2) 0% (0/2) 47% (7/15)
<22.5 30% (7/23) 29% (2/7) 20% (1/5) 29% (10/35)
<25.0 30% (8/27) 22% (2/9) 33% (3/9) 29% (13/45)
>25 24% (8/33) 15% (2/13) 27% (3/11) 23% (13/57)
For samples that were positive for Gram-negative bacteria with Cp >25 (n = 12) the result is presented as >25 by the software, and not with continuous variables.
Data is presented as percentages (No. of SeptiFast positive samples from patients with severe sepsis /No. of SeptiFast positive samples in total, according to cut-off).







































Figure 1 Number of samples from patients with severe sepsis/septic shock in relation to positive predictive values. Bars in blue show
cumulative numbers of SeptiFast positive samples from patients with severe sepsis/septic shock in the entire study population at different Cp
cut-off values. The green line shows positive predictive values for detection of severe sepsis/septic shock at different Cp cut-off values.
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fungal DNA, were used in the SeptiFast test, as recom-
mended by the manufacturer.
PCR positivity, even when BC remains negative, was
recently found to correlate to disease severity [27]. This
suggests that such a result probably often represents a
relevant bloodstream infection that BC may have failed
to detect.
In the present study there were several positive PCR
tests with high Cp values and without microbiological
verification, and it is difficult to determine their clin-
ical significance. Many of the BC negative cases had
other microbiological or clinical support, but not all of
them [21].
A study cohort where all PCR positive samples were
supported by a positive BC, or other microbiological or
clinical verification, would have been optimal.
One possible explanation for a negative PCR despite a
positive BC might be that the sample volume of approxi-
mately one mL, compared with 20 mL in BC, is not always
sufficient to detect bacterial DNA, when the bacterial load
is low. This is a limitation with SeptiFast and other PCR
assays for bacterial identification directly on blood sam-
ples, leading to suboptimal sensitivities. Other reasons
for a false-negative SeptiFast test might be competition
for the PCR by human DNA in the blood, problems
with the selection of species-specific targets in the test,
or, for Gram-positive bacteria, especially Streptococcus
species, a detection level set too high.
The most apparent advantage of molecular methods
compared with BC is the possibility of a rapid diagnosis
of aetiology with results available within hours. The time
required to conduct a SeptiFast analysis is about 6 hours,
but this assumes optimal laboratory conditions, which is
difficult to obtain in everyday clinical practice.
A disadvantage with PCR techniques compared with
BC is the lack of drug susceptibility testing. However,
genetic determinants of drug resistance can be found by
PCR. SeptiFast has an optional step where S. aureus
positive samples are tested for the presence of the mecA
gene in a subsequent run. We did not carry out this step
in our study as the frequency of methicillin resistant S.
aureus (MRSA) is low in Sweden, and all BC positive cases
with S. aureus were methicillin sensitive in the present
study.
Today, little is known about the bacterial DNA load
in S. aureus bacteraemia [19]. In terms of the focus of S.
aureus bloodstream infection, a correlation has been
shown between time to positivity in BC, used as a surro-
gate marker for bacterial load, and endovascular infection
sources, such as endocarditis [28]. It was recently shown
that a persistently positive SeptiFast test can predict endo-
vascular complications in patients with S. aureus blood-
stream infections [29]. The endocarditis group in our
study was very small, only four patients. Despite this, a
correlation was found showing that Cp values seem to be
lower in endocarditis than in other S. aureus bloodstream
infections. Such correlation might be of significant clinical
value as there is always a considerable risk of endocarditis
in S. aureus blood stream infections. The Cp value could
indicate when endocarditis should be suspected, and help
distinguish which patients should be subjected to further
diagnostics.
Our study has several limitations, the most important
of which is the limited size of the study cohort. Further
studies are needed to confirm the correlation between
Cp values and disease severity, preferably with larger
study cohorts and a higher proportion of patients with
severe sepsis/septic shock. For certain pathogens the sam-
ple size was too small to enable any statistical analyses for
the specific species. We have chosen to present results for
the largest groups of specific pathogens, for Gram-positive
and Gram-negative pathogens, and for the entire study co-
hort. The manufacturer of the SeptiFast test uses different
Cp cut-offs for different pathogens, and pathogenicity
and growth manner differ between species. Consequently,
the associations we found for groups of pathogens put
together are less reliable than the pathogen-specific
associations.
The positive predictive values are calculated based on
this study cohort, where the prevalence of severe sepsis
was about 30%, and cannot be generalised. The suggested
cut-off level at 17.5 cycles is calculated on this specific
study population and needs further validation in other
studies before it can be applicable in a clinical context.
This value is also lower compared to other real-time PCR
tests since the fluorescence in the SeptiFast test is not
measured during the first six cycles.
The Cp values of the SeptiFast test can only serve as a
positive predictive tool, as high Cp values cannot rule
out severe sepsis/septic shock. In a real scenario, there
would certainly be a number of cases with severe sepsis/
septic shock and negative PCR, due to the limited sensitiv-
ity of the SeptiFast test [21]. As we lack a control group
with such patients, we have not been able to calculate
negative predictive values, which is a limitation.
Concerning the 12 samples that were positive for
Gram-negative bacteria with Cp values >25, we unfortu-
nately have no access to continuous variables. We have
given them a Cp value of 25.0, which is a statistical con-
cern. However, this should not affect the associations
found, as data is presented in medians, and all calculations
compare median values and not means.
Conclusion
Studies have shown that PCR identification using the
SeptiFast test has the potential to become a cost-effective
component in managing sepsis [30-32]. The possible ben-
efits of a more rapid diagnosis of sepsis aetiology would be
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earlier adequate antimicrobial treatment and reduced
mortality. However, there remains a need to optimise the
commercial assays for this purpose, where the most
important issue would be to obtain better sensitivities.
In addition, we emphasise the need for further evaluation
of quantitative data and its clinical implications.
Today the results of commercial PCR tests for sepsis
diagnostics do not give information about the amount of
DNA of the identified pathogen. Our results indicate
that such quantification data would provide valuable infor-
mation to the user concerning the clinical significance of a
positive test. As an improvement of such tests, we suggest
introducing automatic presentation of Cp values (or Ct
values when other PCR platforms than the LightCycler are
used) as a part of the test result. The manufacturer of The
SeptiFast test can easily derive Cp values, and it should be
possible to routinely share this information with the user.
It would be even better in terms of easier interpretation,
if a calculation of the bacterial DNA load, measured in
copies/mL, was included in the test result.
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